SCHEDULE 13D/A: Robert J. Palmisano and Family Entity Disclose 5.7% Stake in AEON Biopharma

Robert J. Palmisano and The Palmisano Family, LLC have filed an amended Schedule 13D, revealing a beneficial ownership of 2,265,000 shares, representing approximately 5.7% of AEON Biopharma, Inc.'s Class A Common Stock.

Summary

• Robert J. Palmisano and The Palmisano Family, LLC collectively beneficially own 2,265,000 shares of AEON Biopharma, Inc.'s Class A Common Stock.
• This ownership represents approximately 5.67% of the Company's outstanding shares, based on 39,970,693 shares outstanding as of November 11, 2024.
• The shares were acquired through pro rata distributions from Priveterra, with 1,115,000 shares received on July 19, 2024, and an additional 1,150,000 shares on July 25, 2024.
• Mr. Palmisano, as the sole manager of The Palmisano Family, LLC, holds sole investment and voting power over these shares.
• An RSU Award of 36,021 shares granted to Mr. Palmisano on August 31, 2024, is not included in the beneficial ownership calculation for this filing as it does not vest within 60 days of the Schedule 13D filing date.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It provides no positive or negative operational or financial news about the company itself, only an update on a significant shareholder's position.

Positives

• A key individual, Robert J. Palmisano, and his family entity have established a significant beneficial ownership stake of 5.7% in AEON Biopharma, Inc., potentially signaling confidence in the company's future.

Future Outlook

The document notes that 36,021 shares underlying an RSU Award granted to Mr. Palmisano on August 31, 2024, will vest in full on the second anniversary of the grant date, subject to his continued service to the Issuer.

Industry Context

This filing is a standard disclosure of a significant ownership stake by an individual and related entity in a publicly traded company, which is a routine event in the financial markets and does not directly relate to broader industry trends beyond the specific company's ownership structure.

Corporate Governance

Related Party Transactions

• The Palmisano Family, LLC received pro rata distributions of shares from Priveterra on July 19, 2024, and July 25, 2024. While Priveterra is not explicitly defined as a related party to AEON Biopharma in this document, the distribution of shares to a significant shareholder's family entity could be considered a related transaction in a broader context.

Stakeholder Impact

• Shareholders: The disclosure of a significant beneficial ownership stake by Robert J. Palmisano, a key individual, may be viewed positively as a sign of insider confidence in the company's long-term prospects.

Next Steps

• The RSU Award of 36,021 shares granted to Mr. Palmisano is expected to vest in full on August 31, 2026 (the second anniversary of the Grant Date), contingent on his continued service to AEON Biopharma, Inc.

Key Dates

Keywords

AEON Biopharma, Robert J Palmisano, The Palmisano Family LLC, Beneficial Ownership, Schedule 13D, Stock Ownership, SEC Filing, Class A Common Stock